Director Forsyth Douglas purchased 75,000 shares across 2 transactions for $1,037,328.16, increasing stake by 50.1% amid -64.8% decline from 52-week high.
Forsyth Douglas, a director at Inhibrx Biosciences, executed 2 separate purchases totaling 75,000 shares for $1,037,328.16 on August 22-23, 2024, at prices of $12.89 and $14.07, raising his post-transaction holdings to 224,564 shares from 149,564 shares. This 50.1% increase in his equity stake is noteworthy given that the stock is currently trading at $13.93, down 64.8% from its 52-week high of $39.56 and down 59.4% over the past 90 days. The material accumulation at depressed levels—within the lower half of the 52-week range—by a director represents a substantial commitment of personal capital during a period of significant price deterioration, though the company's reported financials show extreme disparity (Revenue $100,000.00 for the latest quarter against Net income of $1,858,011,000.00), which warrants scrutiny regarding the data's consistency and the business's actual financial condition.